Oxford Biomedica PLC PDMR / PCA Dealing (8662N)
September 27 2023 - 7:03AM
UK Regulatory
TIDMOXB
RNS Number : 8662N
Oxford Biomedica PLC
27 September 2023
PDMR / PCA Dealing
Oxford, UK - 27 September 2023: Oxford Biomedica plc ("Oxford
Biomedica" or " the Company") (LSE:OXB), a quality and
innovation-led viral vector CDMO, today announces that Sandra
Juliet Ferera Hayden, a person closely associated with Michael
Hayden, a Non-Executive Director of the Company, purchased ordinary
shares in the Company yesterday.
The below notification, made in accordance with the requirements
of the EU Market Abuse Regulation, give further details of the
number of ordinary shares purchased.
1. Details of the Person Closely Associated ("PCA")
a) Name Sandra Juliet Ferera Hayden
----------------------------- ----------------------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------------------
a) Position/status This notification concerns Sandra Juliet
Ferera Hayden in her capacity as a
person closely associated with a person
discharging managerial responsibilities.
The person discharging managerial responsibilities
is Michael Hayden, a Non-Executive
Director at the Company. The association
arises by virtue of Sandra Juliet Ferera
Hayden being the spouse of Mr. Hayden.
----------------------------- ----------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ----------------------------------------------------
3. Details of the Issuer
-----------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ----------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ----------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
-----------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial
instrument
ISIN: GB00BDFBVT43
Identification
code
----------------------------- ----------------------------------------------------
b) Nature of the P urchase of shares
transaction
----------------------------- ----------------------------------------------------
c) Currency GBP - British pound
----------------------------- ----------------------------------------------------
d) Price(s) and volumes(s) Price(s) Volume(s)
GBP2 .935 12,000
----------
----------------------------- ----------------------------------------------------
e) Aggregated information
* Aggregate volume 12,000
* Aggregated total GBP35,220
----------------------------- ----------------------------------------------------
f) Date of the transaction 2023-09-2 6
----------------------------- ----------------------------------------------------
g) Place of the transaction London Stock Exchange, Main Market
(XLON)
----------------------------- ----------------------------------------------------
-Ends-
For further information, please
contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell
and gene therapy CDMO with a mission to enable its clients to
deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the
Company has more than 25 years of experience in viral vectors; the
driving force behind the majority of gene therapies. The Company
collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV) and adenoviral vectors. Oxford
Biomedica's world-class capabilities span from early-stage
development to commercialisation. These capabilities are supported
by robust quality-assurance systems, analytical methods and depth
of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in
Oxford, UK. It has locations across Oxfordshire, UK and near
Boston, MA, US. Learn more at www.oxb.com , www.oxbsolutions.com ,
and follow us on LinkedIn and YouTube .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHPPUMABUPWGUM
(END) Dow Jones Newswires
September 27, 2023 07:03 ET (11:03 GMT)
Oxford Biomedica (AQSE:OXB.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024
Oxford Biomedica (AQSE:OXB.GB)
Historical Stock Chart
From Dec 2023 to Dec 2024
